Evidence map›Paper›PMID 40535967›Full record

ArticleClinical epidemiology2025

Framework for Exploration of Statistical Heterogeneity in Multi-Database Studies: A Case Study Using EXACOS-CV Studies.

Kirsty Marie Rhodes, Edeltraut Garbe, Hana Müllerová, Paul Ekwaru, Nils Kossack, Brenda N Baak, Muriel Lobier, Nathaniel M Hawkins, Clementine Nordon

Abstract read
In one paragraph

Article in Clinical epidemiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Kirsty Marie RhodesReal-World Science and Analytics, BioPharmaceuticals Medical, AstraZeneca, Cambridge, UK.ORCID 0000-0002-8568-4979
Edeltraut GarbeLeibniz Institute for Prevention Research and Epidemiology - BIPS, Bremen, Germany.ORCID 0000-0002-5408-1462
Hana MüllerováRespiratory Evidence Strategy, BioPharmaceuticals Medical, AstraZeneca, Cambridge, UK.ORCID 0000-0002-0949-0101
Paul EkwaruMedlior Health Outcomes Research Ltd., Calgary, AB, Canada.ORCID 0000-0001-7385-4769
Nils KossackWIG2 Institute, Leipzig, Germany.ORCID 0000-0002-9521-3898
Brenda N BaakPHARMO Institute for Drug Outcomes Research, Utrecht, Netherlands.ORCID 0000-0003-3146-2462
Muriel LobierBiostatistics, Real World Solutions, IQVIA, Espoo, Finland.ORCID 0000-0003-1174-1288
Nathaniel M HawkinsDivision of Cardiology, Centre for Cardiovascular Innovation, University of British Columbia, Vancouver, BC, Canada.ORCID 0000-0003-1286-2014
Clementine NordonRespiratory Evidence Strategy, BioPharmaceuticals Medical, AstraZeneca, Cambridge, UK.ORCID 0000-0001-9441-9723

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: Multi-database studies may provide heterogeneous results despite using common protocols, leading to challenges in interpretation, but also providing an opportunity to gain insights on populations or healthcare systems. The objectives of these analyses were to develop a framework for exploring sources of statistical heterogeneity and apply it to the multi-database EXACOS-CV (EXAcerbations of COPD and their OutcomeS on CardioVascular diseases) program. Methods: A conceptual framework to systematically assess sources of statistical heterogeneity in multi-database studies was developed. This framework distinguishes between methodological diversity and true clinical variation. Methodological diversity includes differences in study design and database selection, while true variation considers population and healthcare differences. Possible sources of methodological diversity were identified via a novel checklist and explored. In turn, hypotheses were generated about true variation. The framework and checklist were applied to EXACOS-CV cohort studies in Germany, Canada, the Netherlands, and Spain which deviated least from the common protocol and so were included. Focus was on adjusted hazard ratios (aHR) for post-exacerbation associations with decompensated heart failure (HF) and all-cause death, for which results were most and least heterogeneous, respectively. Results: Across EXACOS-CV studies, the adjusted hazard ratios (aHR) for HF in the first 1-7 days post-exacerbation, compared to non-exacerbation periods, ranged from 2.6 (95% CI, 2.3, 2.9) in Germany to 72.3 (64.4, 81.2) in Canada, and the association with death, relative to non-exacerbation periods, ranged from 3.5 (2.4, 5.3) in the Netherlands to 22.1 (19.9, 24.4) in Spain. Completed methodological diversity checklists linked differences in aHRs to possible variation in ability to capture pre-existing cardiovascular comorbidities across studies, as well as differences in confounder measurement. Standardizing adjusted models across studies did not fully explain heterogeneity, suggesting other contributing factors. Heterogeneity may result from genuine variation in prevalence of CV disease. It was hypothesized that patients with pre-existing CV disease have more accurate diagnoses and management of post-exacerbation CV events, possibly leading to lower risks of such events. Conclusion: Multi-database studies can provide directional insights on the study research question while considering healthcare system and population differences. The developed framework aids assessment of heterogeneity sources.

Indexed as

cardiovascular outcomeschronic obstructive pulmonary diseaseexacerbationheterogeneitymulti-database studyreal-world data

Identifiers

PMID40535967
PMCPMC12176119

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.